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Immunoscintigraphy in axial spondyloarthritis: a 
new imaging modality for 
sacroiliac inflammation
Imaging of sacroiliac joints (SIJ) is one of the cornerstones 
in early recognition of axial spondyloarthritis (axSpA).1 
Currently, MRI is the preferred technique to visualise bone 
marrow oedema (BME), which can be defined as sacroiliitis 
when certain criteria are met.2 However, the definition of 
sacroiliitis as being ‘highly suggestive for axSpA’ has limita-
tions in situations when BME is subtle or when SpA- like BME 
lesions are present due to other conditions such as mechan-
ical stress.3 4 This underscores the need for additional and 
more specific imaging modalities. Given the marked efficacy 
of tumour necrosis factor (TNF) inhibitors in axSpA, with 
approximately 50% of patients achieving a clinically important 
response,5 we reasoned that molecular imaging studies aiming 
at selectively visualising TNFα in vivo at the site of clinical 
inflammation could be an attractive approach. Therefore, 
we set up a proof- of- concept study in axSpA patients by 
performing scintigraphy with Tc99m- labelled certolizumab 
pegol (CZP) as tracer. We investigated the agreement between 
tracer uptake on immunoscintigrapy and BME on MRI at 
the same localisation of the SIJ. CZP was conjugated with 
succinimidyl-6- hydrazino- nicotinamide (S- HYNIC), a bifunc-
tional crosslinker. Subsequently, solutions of 1.25 mg conju-
gated S- HYNIC CZP were used to radiolabel with Tc99m. 
Seven axSpA patients (71.4% male; mean age 36±5.7 years; 
mean disease duration 9.3±4.8 years) were intravenously 
injected with 740 MBq Tc99m- radiolabelled CZP (10.6 MBq/
kg) in a similar way as in a classical bone scintigraphy proce-
dure. Static images with single photon emission tomography 
(SPECT)/CT of SIJ were acquired 4–6 hours postinjection. No 
procedure- related adverse events were observed. Of note, all 
patients had high disease activity (mean ASDAS 3.5±0.7) and 
five out of seven patients failed on at least one TNF inhibitor 
at inclusion. Uptake of tracer was scored semiquantitatively, 
per SIJ quadrant: 0=no uptake, 1=faint uptake or 2=clear 
uptake. BME on MRI was scored per SIJ quadrant according 
to the SPARCC method including depth and intensity scores.6 
Agreement between MRI–SIJ and immunoscintigraphy was 
calculated (kappa; percentage agreement) for all quadrants 
separately using a cut- off of ≥1 for MRI as well as for immu-
noscintigraphic scores.
A mean score of 12.9±13.2 BME lesions and a mean score 
for tracer uptake on immunoscintigraphy of 4.86±5.4 were 
found. Figure 1 shows the distribution of BME on MRI–SIJ 
and tracer uptake on immunoscintigraphy together with the 
fusion image of MRI and SPECT. Two out of seven patients 
had no BME on MRI and also no tracer uptake on scintig-
raphy. Interestingly, one of those presented with a partial 
ankylosis of the SIJ, suggesting that in vivo detection of TNF 
does not correlate with bone formation (figure 1). The agree-
ment between tracer uptake and MRI–SIJ BME was good for 
all quadrants separately (figure 1). When taking all quadrants 
in consideration, we found a good correlation (kappa=0.82; 
total agreement=91.1%). Clear tracer uptake (score 2) was 
correlated with deep BME lesions on MRI–SIJ with a Spear-
man’s rho correlation of 0.986 (p<0.00) and 0.956 (p<0.00) 
for left and right SIJs, respectively.
At present, there is no agreement on the minimum BME 
size necessary to be defined as ‘positive’ but our study suggests 
that ‘deep’ BME lesions on MRI–SIJs are more suggestive 
of axSpA. Taking these extended lesions into account, very 
high agreement between tracer uptake and MRI–SIJ BME 
lesions was found. Notwithstanding the study’s limitations 
(low sample size and lack of a control group), in an era of 
evidence- based medicine, there is still an unmet need to deter-
mine whether observed BME on MRI is caused by underlying 
cytokine- driven inflammation which can be visualised by this 
immunoscintigraphic approach. This findings support a more 
rational approach of determining the most appropriate biolog-
ical treatment for an individual patient.
In summary, our study showed the presence of TNF- driven 
active disease in SIJs in axSpA patients by using a non- invasive 
immunoscintigraphic technique with radiolabelled CZP. Espe-
cially with deep BME lesions on MRI–SIJ, agreement with 
tracer take- up was excellent.
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Figure 1 (A,B) MRI and immunoscintigraphy of the sacroiliac joints 
after administration of Tc99m- radiolabelled certolizumab pegol in a 
patient with active axial spondyloarthritis (A) and in one with partial 
ankylosis (B). (a) MRI STIR sequence visualising extensive bone marrow 
oedema at both sacroiliac joints (A) and no bone marrow oedema 
(B). (b) Distribution of Tc99m- radiolabelled certolizumab pegol in 
sacroiliac joints 4–6 hours postinjection depicting clear uptake (A) and 
no uptake (B). (c) Fusion of the MRI and immunoscintigraphic SPECT 
image. (C) Immunoscintigraphic image 4–6 hours postinjection of 
Tc99m- radiolabelled certolizumab pegol of hands of a patient with axial 
spondyloarthritis with concomitant clinically dactylitis of the fourth digit 
depicting marked tracer uptake in both the joints and the accompanying 
flexor tendon of that digit. (D) SPECT- CT 4–6 hours postinjection of 
Tc99m- radiolabelled certolizumab pegol of the right foot in a patient 
with spondyloarthritis and concomitant enthesitis of the Achilles tendon 
depicting distinct tracer uptake at the insertion of the Achilles tendon. 
Below: Table with agreement on the presence of BME on MRI–SIJ 
and tracer uptake on the immunoscintigraphy at patient level and 
at quadrant level. BME, bone marrow oedema; SPECT, single photon 
emission tomography; STIR, short tau inversion recovery.
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